Original Report

Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine†

  1. Jocelyne Moisan PhD1,2,*,
  2. Jean-Pierre Grégoire MPH, PhD1,2,
  3. Michel Gaudet MSc2,
  4. Dan Cooper MSc1,2

Article first published online: 22 MAR 2005

DOI: 10.1002/pds.1093

Issue

Pharmacoepidemiology and Drug Safety

Pharmacoepidemiology and Drug Safety

Volume 14, Issue 6, pages 427–436, June 2005

Additional Information

How to Cite

Moisan, J., Grégoire, J.-P., Gaudet, M. and Cooper, D. (2005), Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine. Pharmacoepidemiology and Drug Safety, 14: 427–436. doi: 10.1002/pds.1093

Author Information

  1. 1

    Faculty of Pharmacy, Université Laval, Québec, Que., Canada

  2. 2

    Population Health Research Unit, Centre hospitalier affilié universitaire de Québec, Que., Canada

*Unité de recherche en santé des populations, Hôpital Saint-Sacrement du CHA, 1050, chemin Sainte-Foy, Québec, Que., Canada G1S 4L8.

  1. †

    No conflict of interest was declared.

Publication History

  1. Issue published online: 27 MAY 2005
  2. Article first published online: 22 MAR 2005
  3. Manuscript Accepted: 20 DEC 2004
  4. Manuscript Revised: 6 DEC 2004
  5. Manuscript Received: 15 APR 2004

Funded by

  • Janssen-Ortho, Inc.

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

Get PDF (170K)

Keywords:

  • diabetes mellitus;
  • dyslipidemia;
  • atypical antipsychotics;
  • population-based;
  • cohort study

Abstract

Purpose

To compare the incidence rates of diabetes mellitus and dyslipidemia in ambulatory first-time users of risperidone and olanzapine.

Methods

The database for the Prescription Drug Insurance Plan in the province of Quebec was used as the data source for a population-based cohort study. Denominalized data were extracted for all ambulatory patients who first received an atypical antipsychotic between 1 January 1997 and 31 August 1999. Eligible patients were categorized as taking: no antidiabetic medication; no lipid reducing medication; neither type of medication. Those who started to use an outcome drug (an antidiabetic or lipid-lowering medication) before the end of the follow-up period (31 August 2000) were considered to have developed the corresponding outcome disease. Incidence rate ratios (IRR) (and 95% confidence intervals) for initiating antihyperglycemic or lipid-lowering drug treatment, or both were calculated. Outcomes on risperidone were compared to those on olanzapine.

Results

A total of 19 582 eligible patients were included in the analysis. Relative to risperidone, olanzapine was associated with a higher risk of initiating a pharmacologic treatment for diabetes [IRR: 1.33 (1.03–1.74)], dyslipidemia [IRR: 1.49 (1.22–1.83)], or either condition [1.47 (1.23–1.76)].

Conclusions

Olanzapine seems to be associated with a higher risk of developing diabetes and/or dyslipidemia than risperidone. Further prospective studies are needed to rigorously assess the safety of olanzapine. Copyright © 2005 John Wiley & Sons, Ltd.

Get PDF (170K)